Startups
Globavir Biosciences is a San Francisco Bay Area based company committed to the development of therapeutics and diagnostics for the treatment of global infectious diseases. Globavir's development strategy harnesses the advantages offered by the 505(b)2 regulatory pathway, allowing for rapid development of new therapies. Globavir is initially focused on the treatment of dengue virus infection, a potentially lethal disease infecting 390 million patients annually. Through the combination of our proprietary diagnostic technology and advanced therapeutic candidates, Globavir is ideally positioned to rapidly impact the clinical landscape for Dengue patients. Globavir's platform discovery technologies have further identified candidate compounds with efficacy in additional viral indications, including West Nile, Japanese Encephalitis, Ebola, Marburg, and Hunta viruses.
Overview
Location
United States, California, Los Altos
Investors 2
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| StartX | startx.com |
Mentions in press and media 2
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 18, 2015 | Andreessen Horowitz Gets A New GP, And A New Fund | Andreessen Horowitz is making a big move into biotech, and it’s using a $200 million new fund called the AH Bio Fund – and new general partner, Vijay Pande — to plant its stake in the ground. The fund will be used to invest in mostly early-... |
Reviews 0
FAQ about Globavir Biosciences, Inc.
Who has invested in Globavir Biosciences, Inc.?
Parsers VC lists 2 investors of Globavir Biosciences, Inc., among them StartX.
What has the press written about Globavir Biosciences, Inc.?
Parsers VC has collected 2 articles mentioning Globavir Biosciences, Inc., among them “Andreessen Horowitz Gets A New GP, And A New Fund” (Nov 18, 2015).
Is Globavir Biosciences, Inc. still active?
Yes, Globavir Biosciences, Inc. is active; its latest activity on Parsers VC dates from Jun 21, 2017.